Last updated: February 27, 2026
What is NDC 42799-0958?
NDC 42799-0958 is the National Drug Code for a specific drug product approved by the FDA. Based on available data, this NDC corresponds to Bupropion Hydrochloride Extended-Release (XR), 150 mg. It is approved for major depression and smoking cessation support.
Market Overview
Market Size and Demand
The Bupropion XR segment is established within the antidepressant and smoking cessation markets. As of 2022, the global antidepressant market was valued at approximately $18 billion, with Bupropion accounting for roughly 7% ($1.26 billion).
The smoking cessation market approaches $2 billion globally, with Bupropion (e.g., Zyban) representing a significant portion, estimated at around 30%.
Total prescriptions in the US for Bupropion XR formulations reached 15 million in 2022, reflecting sustained demand. Growth is driven by increased awareness of mental health treatments and smoking cessation programs.
Competitive Landscape
Major competing drugs include:
- Varenicline (Chantix)
- Nicotine Replacement Therapy (gum, patches)
- Other antidepressants: SSRIs like sertraline and escitalopram
Generic versions of Bupropion XR became widely available post-patent expiration in 2012, driving price competition.
Regulatory Status
The drug has FDA approval for depression and smoking cessation, with no recent patent protections. While specific formulations like the NDC in question are subject to manufacturing and distribution agreements, the overall market faces competitive generic pressures.
Price Analysis
Current Pricing (2023)
| Packaging |
Wholesale Acquisition Cost (WAC) |
Estimated Retail Price (ERx) |
Average Pharmacist Acquisition Cost |
| 150 mg, 30-count |
$30.00 per bottle |
$45.00 |
$20.00 |
Note: Prices vary by supplier, insurance coverage, and pharmacy discounts.
Historical Trends
Since patent expiration in 2012, prices have declined markedly, with stabilized generic pricing:
- 2012: Approx. $60 for 30 tablets (brand)
- 2018: Average $40 (generic)
- 2023: $30 (generic)
Price Drivers
- Entry of multiple generic manufacturers
- Medicaid and Medicare drug price negotiations
- Increased pharmacy discounting and rebate programs
Future Price Projections (2024-2028)
Based on historical trends and market saturation:
-
Short-term (2024–2025): Prices stabilize around $25–$30 for 30 tablets due to manufacturing efficiencies and market saturation.
-
Mid-term (2026–2028): Slight decline possible, reaching approximately $20–$25, driven by further generic competition and pharmacy benefit management strategies.
Potential Impact of Policy and Market Dynamics
- formulary margin pressures: Cost containment policies may push prices below current levels.
- Supply chain factors: Raw material costs or manufacturing disruptions could cause minor price fluctuations.
- New formulation developments: Patent or exclusivity periods for novel formulations could temporarily elevate prices but unlikely for the existing NDC.
Key Market Trends
- Growing focus on mental health and smoking cessation expands overall demand.
- Price competition among generics maintains downward pressure.
- Insurance and pharmacy benefit managers increasingly negotiate rebates, reducing net prices.
Key Takeaways
- NDC 42799-0958, representing Bupropion XR 150 mg, is widely available as a generic.
- Prices have declined sharply since patent expiry, stabilizing around $20–$30 for a 30-day supply.
- Future pricing will likely remain in this range, with minor declines fueled by competition.
- Market growth is driven by demand for depression and smoking cessation therapies.
- Price trends are sensitive to regulatory, supply chain, and formulary dynamics.
FAQs
1. What factors influence the price of this drug?
Market saturation, competition among generic manufacturers, insurance reimbursement policies, and pharmacy discounts primarily influence its price.
2. How does the price of this generic compare to the branded version?
The branded version historically cost about $60–$70 for 30 tablets, while the generic now ranges $20–$30.
3. Are there any upcoming patent protections that could affect prices?
No. The original patent expired in 2012, and current formulations are off patent.
4. How is the market demand expected to change?
Demand remains stable due to ongoing needs in depression treatment and smoking cessation programs.
5. Will new formulations impact the price of NDC 42799-0958?
Possible, but unlikely to directly influence this specific formulation unless new patents or exclusivities are granted.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
- Millennium Research Group. (2023). Antidepressants and Smoking Cessation: Market Insights.
- Medicaid Drug Rebate Program. (2023). Pricing and Rebates Data.
- Retail Pharmacy Pricing Reports. (2023).
